Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00712270 · ClinicalTrials.gov registry record · Phase 4
Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia
A Phase 4 study, sponsored by Kettering Health Network.
- Terminated
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT00712270 is a Phase 4 study that was terminated before completion, run by Kettering Health Network. The registered enrollment target is 21 participants.
The verdict
NCT00712270, a Phase 4 study, was terminated before completion, sponsored by Kettering Health Network.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study is being conducted to find a way to predict how individual schizophrenic patients will respond if they are treated with different types of antipsychotic drugs. This could help doctors prescribe the medication that will work best for each individual.
Interventions
- DRUG Risperidone
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2005-04 |
| Est. Completion | 2010-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00712270
The ClinicalTrials.gov registry entry for NCT00712270 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kettering Health Network, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Risperidone is the first listed.
NCT00712270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00712270 about?
NCT00712270 is a clinical study titled "Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia". This study is being conducted to find a way to predict how individual schizophrenic patients will respond if they are treated with different types of antipsychotic drugs. This could help doctors prescribe the medication that will work best for each individual.
What is the current status of trial NCT00712270?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2005-04. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00712270?
The interventions under investigation include: Risperidone (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00712270?
This trial is sponsored by Kettering Health Network, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.